<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00577577</url>
  </required_header>
  <id_info>
    <org_study_id>INSM-110-1001</org_study_id>
    <nct_id>NCT00577577</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1</brief_title>
  <official_title>A Placebo Controlled, Randomized, Double-Blind Phase II Clinical Trial to Evaluate Tolerability, Safety and Efficacy Endpoints After Administration of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) for 24 Weeks in Adults With Myotonic Dystrophy Type 1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Insmed Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Muscular Dystrophy Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Insmed Incorporated</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the effects of rhIGF-I/rhIGFBP-3 treatment for 24 weeks on endurance,
      ambulation, cognitive functioning, insulin resistance, lipid levels, muscle function and
      strength, pain, gastrointestinal functioning, and quality of life endpoints in DM1 patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Efficacy Measures:

      Endurance, Ambulation, Cognitive function, Insulin resistance, Cholesterol and triglycerides,
      Muscle function and strength, Pain, Gastrointestinal function, Quality of life

      MINIMUM INCLUSION CRITERIA

        1. A diagnosis of DM1, confirmed by DM1 genetic mutation

        2. Age 21 to 65 years (inclusive)

        3. Ability to walk 30 feet - assistance with cane and/or leg bracing permitted

        4. Able to self-administer study medication by subcutaneous injection or caregiver is
           available to administer study medication
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>December 2007</start_date>
  <completion_date type="Anticipated">March 2009</completion_date>
  <primary_completion_date type="Anticipated">March 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endurance</measure>
    <time_frame>Six Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ambulation</measure>
    <time_frame>Six Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cognitive function</measure>
    <time_frame>Six months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin Resistance</measure>
    <time_frame>Six Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cholesterol and triglycerides</measure>
    <time_frame>Six Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Muscle function and strength</measure>
    <time_frame>Six months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain</measure>
    <time_frame>Six Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Gastrointestinal function</measure>
    <time_frame>Six Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>Six Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>Six Months</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Myotonic Dystrophy Type 1</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhIGF-I/rhIGFBP-3</intervention_name>
    <description>1.0 mg/kg rhIGF-I/rhIGFBP-3 or placebo daily, subcutaneous injections from baseline through the last day of the end of study visit.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>1.0 mg/kg rhIGF-I/rhIGFBP-3 or placebo daily, subcutaneous injections from baseline through the last day of the end of study visit.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (list is not inclusive):

          -  A diagnosis of DM1, confirmed by DM1 genetic mutation

          -  Ability to walk 30 feet - assistance with cane and/or leg bracing permitted

          -  Able to self-administer study medication by subcutaneous injection or caregiver is
             available to administer study medication

        Exclusion Criteria (list is not inclusive):

          -  Congenital DM1

          -  Weight greater than 100 kg or body mass index greater than 30 kg/m2

          -  Prior treatment with glucocorticoids, anabolic steroids, testosterone, growth hormone,
             investigational agent within 60 days of screening

          -  Current diagnosis or history of malignancy expect for surgically cured skin cancer or
             pilomatricoma

          -  Changes in lipid lowering medications during the 3 months prior to screening

          -  Diaphragmatic weakness such that patients are unable to tolerate the supine position,
             or swallowing impairment such that patients are unable to maintain nutrition without
             use of gastrostomy.

          -  Major psychiatric illness (major depression, bipolar disorder or schizophrenia) within
             twelve months of screening

          -  History of non-compliance with other therapies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Moxley, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Rochester Neuromuscular Disease Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California Irvine Medical Center; MDA, ALS and Neuromuscular Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University Medical School</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester, Neuromuscular Disease Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregan Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universit of Texas Medical Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555-0539</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2007</study_first_submitted>
  <study_first_submitted_qc>December 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2007</study_first_posted>
  <last_update_submitted>July 21, 2008</last_update_submitted>
  <last_update_submitted_qc>July 21, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 23, 2008</last_update_posted>
  <responsible_party>
    <name_title>Christy ONeal, Study Manager</name_title>
    <organization>Insmed Incorporated</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myotonic Dystrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Mitogens</mesh_term>
    <mesh_term>Mecasermin</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>July 5, 2017</submitted>
    <returned>August 1, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

